Comparison of CT Volumetry and RECIST to Predict the Treatment Response and Overall Survival in Gastric Cancer Liver Metastases위암 간전이 환자의 반응평가와 생존율 예측을 위한 종양 부피 측정과 RECIST 기준의 비교 연구
- Other Titles
- 위암 간전이 환자의 반응평가와 생존율 예측을 위한 종양 부피 측정과 RECIST 기준의 비교 연구
- Authors
- Yu, Sung Hyun; Choi, Seung Joon; Noh, HeeYeon; Lee, In Seon; Park, So Hyun; Kim, Se Jong
- Issue Date
- Mar-2021
- Publisher
- Korean Radiological Society
- Keywords
- Chemotherapy; Gastric cancer; Liver neoplasm; Survival
- Citation
- Journal of the Korean Society of Radiology, v.82, no.4, pp.876 - 888
- Journal Title
- Journal of the Korean Society of Radiology
- Volume
- 82
- Number
- 4
- Start Page
- 876
- End Page
- 888
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80909
- DOI
- 10.3348/JKSR.2020.0085
- ISSN
- 1738-2637
- Abstract
- Purpose The aim of this study was to compare the diameter and volume of liver metastases on CT images in relation to overall survival and tumor response in patients with gastric cancer liver metastases (GCLM) treated with chemotherapy. Materials and Methods We recruited 43 patients with GCLM who underwent chemotherapy as a first-line treatment. We performed a three-dimensional quantification of the metastases for each patient. An independent survival analysis using the Response Evaluation Criteria in Solid Tumors (RECIST) was performed and compared to volumetric measurements. Overall survival was evaluated using Kaplan-Meier analysis and compared using Cox proportional hazard ratios following univariate analyses. Results When patients were classified as responders or non-responders based on volumetric criteria, the median overall survival was 23.6 months [95% confidence interval (CI), 8.63-38.57] and 7.6 months (95% CI, 3.78-11.42), respectively (p = 0.039). The volumetric analysis and RECIST of the non-progressing and progressing groups showed similar results based on the Kaplan-Meier method (p = 0.006) and the Cox proportional hazard model (p = 0.008). Conclusion Volumetric assessment of liver metastases could be an alternative predictor of overall survival for patients with GCLM treated with chemotherapy. Copyrights © 2021 The Korean Society of Radiology
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80909)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.